

**Independent Auditor's Review Report on Consolidated Unaudited year to date financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors of  
Dr Fresh Assets Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Dr Fresh Assets Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 31<sup>st</sup> December, 2022 and the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> December, 2022 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities:
  - (i) Dr Fresh Assets Limited (Holding Company)
  - (ii) Reverse Age Health Services Pvt Ltd (Subsidiary)
  - (iii) S5 Property Private Limited (Subsidiary)
  - (iv) Dr Fresh Commercial Land Development Pvt Ltd (Subsidiary)
  - (v) SEL International Pte Limited (Subsidiary)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Emphasis of Matter –

We draw attention to

- a) Note No – 3 to the consolidated financial results, relating to 2 subsidiaries whose net worth has eroded, their accounts have been prepared as a going concern.

Our opinion is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial results of one Foreign subsidiary whose Results have not been reviewed, as Review/Audit is not mandatory in the country of its incorporation, its interim financial results reflect total revenue of Rs. 48.00 Lac & Rs. 128.32 Lac, total Net Profit after tax of Rs. 28.35 Lac & Rs. 0.64 Lac and total comprehensive income of Rs. 28.35 Lac & Rs. 0.64 Lac for the quarter ended 31<sup>st</sup> December, 2022 and for the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> December, 2022 respectively as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial results are certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

For B. K. Shroff & Co  
Chartered Accountants  
Firm Registration No. 090378

*Kavita Nangia*

(KAVITA NANGIA)  
PARTNER

Membership Number:-090378

Place: New Delhi

Date : 14.02.2023

UDIN: **23090378BGXOGF1388**





# DR. FRESH ASSETS LIMITED

(Formerly known as Sunehri Exports Limited)

Regd. Off.: B-1/E-24, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi- 110044

Phone: 91-11-41679238, 26940969

E-mail: drfresh@drfreshassets.com website: www.drfreshassets.com

CIN: L74899DL1990PLC042302

## UNAUDITED CONSOLIDATED FINANCIAL RESULTS (REVIEWED) FOR THE THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022

(All figures are Rs in Lakhs except EPS)

Sl. No.	Particulars	Consolidated Quarter Ended			Consolidated Nine Months Ended		Consolidated Year Ended
		31.12.2022 (Reviewed)	30.09.2022 (Reviewed)	31.12.2021 (Reviewed)	31.12.2022 (Reviewed)	31.12.2021 (Reviewed)	31.03.2022 (Audited)
	<b>REVENUE :</b>						
1	Revenue from Operations	96.87	122.99	39.52	440.99	3080.33	3654.54
2	Other Income	58.90	22.01	9.55	101.68	157.93	156.79
3	<b>TOTAL REVENUE (1+2)</b>	<b>155.76</b>	<b>145.00</b>	<b>49.07</b>	<b>542.67</b>	<b>3238.26</b>	<b>3811.33</b>
4	<b>EXPENSES :</b>						
a	Purchase Traded Goods	10.77	10.79	26.88	38.61	193.14	210.66
b	Changes in Inventory of Traded Goods	(4.61)	4.55	(8.17)	34.45	2330.00	2442.00
c	Cost of Material Consumed	-	-	-	-	-	-
d	Employee Benefits Expense	67.86	57.84	46.06	169.85	130.61	176.75
e	Finance Costs	2.69	2.06	4.96	8.76	60.92	84.04
f	Depreciation	4.43	4.43	4.03	13.28	12.05	16.10
g	Other Expenses	6.74	4.41	51.17	96.64	107.03	243.26
	<b>TOTAL EXPENSES</b>	<b>87.87</b>	<b>84.98</b>	<b>126.73</b>	<b>361.60</b>	<b>2853.75</b>	<b>3172.81</b>
5	<b>Profit / (Loss) before Exceptional and Extraordinary items &amp; Tax (3-4)</b>	<b>67.89</b>	<b>60.02</b>	<b>(77.66)</b>	<b>181.07</b>	<b>384.51</b>	<b>638.52</b>
6	Exceptional Items	-	-	-	-	-	-
7	<b>Profit / (Loss) before Tax</b>	<b>67.89</b>	<b>60.02</b>	<b>(77.66)</b>	<b>181.07</b>	<b>384.51</b>	<b>638.52</b>
8	Provision for Taxation						
a	Current Taxes	(4.48)	9.09	-	31.08	82.50	115.97
b	Earlier Year Taxes	0.83	(1.91)	-	(1.08)	-	-
c	Deferred Tax (Assets)/ Liabilities	3.03	8.76	(13.89)	(4.00)	37.77	45.00
9	Add: MAT Credit Entitlement	(9.09)	(0.51)	0.00	(17.15)	2.50	(12.75)
9	<b>Net Profit / (Loss) After Tax (7-8+9)</b>	<b>58.82</b>	<b>43.57</b>	<b>(63.77)</b>	<b>137.91</b>	<b>266.74</b>	<b>464.80</b>
10	<b>Other Comprehensive Income (Net of Tax)</b>						
a	Item that will not be reclassified to profit or loss	(11.03)	264.43	11.93	230.55	94.63	261.95
b	Item that will be reclassified to profit or loss	-	-	-	-	-	-
11	<b>Total Comprehensive Income for the period</b>	<b>47.79</b>	<b>308.00</b>	<b>(51.84)</b>	<b>368.46</b>	<b>361.37</b>	<b>726.75</b>
12	Paid up Equity Share Capital (Face Value Rs. 10/- Per Share)	1077.91	538.96	538.96	1077.91	538.96	538.96
13	Other Equity						3481.86
14	Basic and Diluted EPS for the period, for the year to date and for the previous year (Rs.) *	0.54	0.40	(0.59)	1.27	2.46	4.28

\* During the quarter 1:1 bonus issue made, accordingly EPS for previous periods, year has been adjusted.



**UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2022**

(All figures are Rs in Lakhs except EPS)

Sl. No	Particulars	Consolidated Quarter Ended			Consolidated Nine Months Ended		Consolidated Year Ended
		31.12.2022 (Reviewed)	30.09.2022 (Reviewed)	31.12.2021 (Reviewed)	31.12.2022 (Reviewed)	31.12.2021 (Reviewed)	31.03.2022 (Audited)
1	<b>Segment Revenue</b>						
	Sales & Other Operating Revenue						
	Oral Care Activities	-	-	-	-	-	-
	Trading Activities (including Gold)	31.79	26.34	24.83	263.40	205.75	640.11
	Real Estate Business Related Activities	15.52	15.05	13.95	45.57	2672.14	2667.14
	Others Unallocable	49.56	81.60	0.74	132.02	2.44	127.29
	<b>TOTAL OPERATING REVENUE</b>	<b>96.87</b>	<b>122.99</b>	<b>39.52</b>	<b>440.99</b>	<b>3080.33</b>	<b>3654.54</b>
2	<b>Segment Results</b> (Profit +/- Loss - Before interest & Tax)						
	Oral Care Activities	4.55	(4.70)	(3.47)	(2.57)	(14.74)	(21.37)
	Trading Activities (including Gold)	6.96	(7.38)	(20.66)	137.88	(13.13)	259.04
	Real Estate Business Related Activities	11.01	10.68	6.85	31.97	502.77	427.17
	Others Unallocable	48.08	64.40	(55.22)	22.57	(9.48)	57.72
	<b>Less: Interest(Not) Expenses</b>	<b>70.59</b>	<b>62.99</b>	<b>(72.71)</b>	<b>189.84</b>	<b>466.42</b>	<b>722.66</b>
	Oral Care Activities	-	-	-	-	-	-
	Trading Activities (including Gold)	0.02	-	-	0.04	-	0.07
	Real Estate Business Related Activities	0.86	1.32	4.09	3.63	76.23	79.86
	Others Unallocable	1.81	1.64	0.86	5.11	2.68	4.11
	<b>Loss: Other Unallocable Expenditure net off Unallocable Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>TOTAL PROFIT BEFORE TAX</b>	<b>67.89</b>	<b>60.03</b>	<b>(77.66)</b>	<b>181.07</b>	<b>384.51</b>	<b>638.52</b>
3	<b>Capital Employed (Segment Assets - Segment Liabilities)</b>						
a)	<b>Segment Assets</b>						
	Oral Care Activities	38.94	39.89	42.72	38.94	42.72	41.78
	Trading Activities (including Gold)	1416.63	1391.44	1536.21	1416.63	1536.21	1464.98
	Real Estate Business Related Activities	3431.63	3864.10	3212.28	3431.63	3212.28	3602.02
	Others Unallocable	2239.91	2421.32	2204.05	2239.91	2204.05	2326.48
	<b>Total Segment Assets (a)</b>	<b>7127.11</b>	<b>7716.74</b>	<b>6995.26</b>	<b>7127.11</b>	<b>6995.26</b>	<b>7437.26</b>
b)	<b>Segment Liabilities</b>						
	Oral Care Activities	249.29	249.94	240.40	249.29	248.40	249.66
	Trading Activities (including Gold)	679.48	712.14	885.81	679.48	885.81	751.19
	Real Estate Business Related Activities	1223.95	1222.70	1478.53	1223.95	1478.53	1348.26
	Others Unallocable	554.99	1186.88	716.33	554.99	716.33	1063.22
	<b>Total Segment Liabilities (b)</b>	<b>2707.71</b>	<b>3371.65</b>	<b>3329.06</b>	<b>2707.71</b>	<b>3329.06</b>	<b>3412.32</b>
	<b>TOTAL CAPITAL EMPLOYED IN SEGMENTS (a - b)</b>	<b>4419.40</b>	<b>4346.09</b>	<b>3666.20</b>	<b>4419.40</b>	<b>3666.20</b>	<b>4024.93</b>

**Notes :**

- The above consolidated financial results have been reviewed by the audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2023.
- These financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and relevant amendment rules thereafter.
- With respect to 2 Subsidiary Companies due to continuous losses, network of these companies has eroded. However, management is exploring the possibility to start any viable project and the accounts have been prepared on going concern basis.
- In line with the requirements of Regulation 47(2) of the Listing Regulations, 2015, the results are available on the stock exchanges website (i.e. www.nse-ix.com) and on the company's website (i.e. www.drfreshassets.com).
- During the quarter the company allotted 53,89,553 Equity Shares of Rs. 10/- each by way of bonus issue (record date 07.10.2022) in the ratio of 1: 1.
- Figures of the previous quarter have been regrouped wherever necessary.

Place : DELHI  
Date : 14.02.2023



For Dr. Fresh Assets Limited

Vijay Prakash Pathak  
Whole Time Director  
DIN-07061998

